Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients

被引:108
|
作者
Bal, CS [1 ]
Kumar, A [1 ]
Pant, GS [1 ]
机构
[1] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India
来源
关键词
D O I
10.1210/jc.2003-031152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Remnant ablation can be achieved by either administering an empiric fixed dose or using dosimetry-guided techniques. Because of the technical and logistic difficulties, most centers have adapted the fixed-dose or standard-dose technique for remnant ablation using (131)I. In the late 1970s, low- dose (131)I remnant ablation was introduced, and subsequently many centers confirmed the effectiveness of such therapy. However, the optimal dose (administered activity) of (131)I for remnant ablation is not yet settled. In a randomized clinical trial to find out the smallest possible effective dose for remnant ablation in cases of differentiated thyroid carcinoma, between July 1995 and January 2002, 565 patients were randomized into eight groups according to (131)I administered activity, starting at 15 mCi and increasing activity in increments of 5 mCi until 50 mCi. In the postrandomization phase, 56 patients were excluded from the study for various reasons, and final analysis was done with 509 patients. The mean age of the patients was 37.5+/-12.7 yr with a female to male ratio of 2.6. The surgical procedure was total/near-total thyroidectomy in 72% and subtotal or hemithyroidectomy in the rest. Histology was papillary thyroid carcinoma in 80.6% of patients and follicular thyroid carcinoma in the rest. With one dose of (131)I, remnant ablation was achieved in 59.6, 63.6, 81.4, 83.6, 79.4, 78.3, 84.4, and 81.8% of patients in the 15- to 50-mCi groups, respectively (overall ablation rate, 77.6%). The successful ablation rate was statistically different in patients receiving less than 25 mCi of (131)I compared with those receiving at least 25 mCi [63 of 102 (61.8%) vs. 332 of 407 (81.6%); P=0.006]. However, there was no significant intergroup difference in outcome among patients receiving 25-50 mCi of (131)I. Patients with small tumor size (less than or equal to5 cm), adequate surgery (total/near-total thyroidectomy), and radioiodine neck uptake of less than or equal to 10% had odds ratios of 2.4 [confidence interval (CI), 1.3-3.98], 2.6 (CI, 1.6-4.2), and 2.2 (CI, 1.4-3.5), respectively, for successful remnant ablation. Patients receiving at least 25 mCi of (131)I had a three times better chance of getting remnant ablation than patients receiving lesser activity of (131)I. Any activity of (131)I between 25 and 50 mCi appears to be adequate for remnant ablation.
引用
收藏
页码:1666 / 1673
页数:8
相关论文
共 50 条
  • [1] How small should "small dose" of radioiodine be for remnant ablation in differentiated thyroid carcinoma: A prospective randomized clinical trial in 372 patients.
    Bal, CS
    Kumar, A
    Pant, GS
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 158P - 158P
  • [2] A Randomized Noninferiority Trial To Determine the Optimum Dose of Radioiodine for Remnant Ablation in Differentiated Thyroid Cancer
    Bal, C. S.
    Chandra, P.
    Kumar, A.
    Dwivedi, S. N.
    ENDOCRINE REVIEWS, 2010, 31 (03) : S1675 - S1675
  • [3] Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma
    Taube, A
    Lundell, G
    CANCER, 1997, 79 (01) : 190 - 190
  • [4] Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma
    Bal, C
    Padhy, AK
    Jana, S
    Pant, GS
    Basu, AK
    CANCER, 1996, 77 (12) : 2574 - 2580
  • [5] Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial
    Fallahi, Babak
    Beiki, Davood
    Takavar, Abbas
    Fard-Esfahani, Armaghan
    Gilani, Kianoush Ansari
    Saghari, Mohsen
    Eftekhari, Mohammad
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (03) : 275 - 282
  • [6] The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy
    Fu, Hongliang
    Ma, Chao
    Li, Jianing
    Feng, Fang
    Wu, Shuqi
    Ye, Zhiyi
    Wang, Hui
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 60 (03): : 280 - 284
  • [7] Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
    Frederik A. Verburg
    Markus Dietlein
    Michael Lassmann
    Markus Luster
    Christoph Reiners
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [8] Editorial: Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation
    Haugen, BR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08): : 3665 - 3667
  • [9] Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
    Verburg, Frederik A.
    Dietlein, Markus
    Lassmann, Michael
    Luster, Markus
    Reiners, Christoph
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (03) : 343 - 346
  • [10] Analysis of Critical Parameters for Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Carcinoma
    Mika, A. Valkovic
    Nekic, J.
    Ivankovic, S. Grbac
    Valkovic, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S482 - S482